

DRIEHAUS CAPITAL MANAGEMENT LLCDriehaus Event Driven Fund Portfolio
as of 4/30/2019**Security Name**

ACER THERAPEUTICS IN	COM
ALTICE EUROPE NV	
ALTICE USA INC	CL A
ARGENX SE	SPONSORED ADR
ARRAY BIOPHARMA INC	COM
ASCENA RETAIL GROUP	TERM LOAN 08/21/2022
ASCENDIS PHARMA A S	SPONSORED ADR
ASURION	BANKDEBT 8/04/2025
AVAYA HLDGS CORP	2.2500% 06/15/23
AVAYA HLDGS CORP	COM
BLUEPRINT MEDICINES	COM
BRISTOL-MYERS	SQUIBB CO
CELGENE CORP	
CONSOLIDATED	COMMUNICATIONS
CONSOLIDATED COMMUNI	6.5000% 10/01/22
CURO GROUP HOLDINGS	8.250% 09/01/2025
CYTOKINETICS INC	
EUR FORWARD	CONTRACT 5/07/2019
FGL HOLDINGS	
FLUIDIGM CORP DEL	COM
FOSSIL GROUP INC	TERM LOAN 12/31/2020
GENERAL MTRS CORP	DEB SR CV C ESCROW
GENERAL MTRS CORP	DEB SR CONV B ESCROW
GENWORTH HOLDING INC	7.70% 6/15/20
HC2 HLDGS INC	11.5000% 12/01/21
HC2 HOLDINGS INC	
IDEAYA BIOSCIENCES,	INC. PRIVATE EQUITY
ILFC E-CAPITAL TR I	VAR RT 12/21/65
INSPIRE MED SYS INC	COM
ISHARES NASDAQ	BIOTECHNOLOGY ETF
KEARNY FINL CORP	COM
MYOKARDIA INC	COM
OCEANFIRST FINL CORP	COM
ORCHARD THERAPEUTICS	PLC
PERSPECTA INC	COM
RED HAT INC	COM
SI BONE INC	COM
SPDR S&P REGIONAL	BANKING ETF
SPDR SERIES TRUST	S&P BIOTECH
STATE STREET CORP	VAR RT 6/15/2037
SUTRO BIOPHARMA INC	COM
TURNING POINT THERAP	COM
USB REALTY CORP	VAR RT PERPETUAL
VAPOTHERM INC	COM
VECTOR GROUP LTD	6.1250% 02/01/25
WATERSTONE FINANCIAL	COM
X4 PHARMACEUTICALS	HOLDINGS WARRANTS

Source: Driehaus Capital Management LLC

The portfolio represents holdings for the Driehaus Event Driven Fund (the "Fund") as of the specified date. The Fund assumes no obligation to update or supplement the holdings to reflect subsequent changes. The holdings posted may not represent current or future portfolio composition or holdings and are subject to change without notice. Information on particular holdings may be withheld if it is in the Fund's best interest to do so. The holdings are unaudited and are provided for general information on the Fund. For more information please contact us at 877-779-0079. For information regarding the Fund's policy for valuation of investments and other significant accounting policies, please refer to the Fund's recent Semi-Annual or Annual financial statements.